Search Results - "Egeler, M"

Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module by Egeler, M.D., van Leeuwen, M., Lai-Kwon, J., Eriksson, H., Bartula, I., Elashwah, S., Fox, L., Van Hemelrijck, M., Jefford, M., Lijnsvelt, J., Bagge, A.-S. Lindqvist, Morag, O., Ny, L., Bagge, R. Olofsson, Rogiers, A., Saw, R.P.M., Serpentini, S., Iannopollo, L., Thompson, J., Stiller, H. Tufvesson, Vanlaer, N., van Akkooi, A.C.J., van de Poll-Franse, L.V.

“…We aimed to develop a European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) module tailored for patients with advanced…”
Get full text

Health-state utilities in long-term advanced melanoma survivors comparable with the general population by Egeler, M. D., van de Poll-Franse, L. V., Tissier, R., Rogiers, A., Boers-Sonderen, M. J., van den Eertwegh, A. J., Hospers, G. A., de Groot, J. W. B., Aarts, M. J. B., Kapiteijn, E., Piersma, D., Vreugdenhil, G., van der Veldt, A. A., Suijkerbuijk, K. P. M., Neyns, B., Janssen, K. J., Blank, C. U., Retèl, V. P., Boekhout, A. H.

“…Background Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors…”
Get full text

Acute GvHD: pathogenesis and classification by Ball, L M, Egeler, R M

“…Allogeneic hematopoietic SCT (HSCT) is an established treatment for some children with life-threatening hematological disease, immune deficiencies and inborn…”
Get full text

Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation by Bernardo, M E, Ball, L M, Cometa, A M, Roelofs, H, Zecca, M, Avanzini, M A, Bertaina, A, Vinti, L, Lankester, A, Maccario, R, Ringden, O, Le Blanc, K, Egeler, R M, Fibbe, W E, Locatelli, F

“…When compared with BMT, umbilical cord blood transplantation (UCBT) is associated with a lower rate of engraftment and delayed hematological/immunological…”
Get full text

“One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care by Egeler, M. D., Boomstra, E., Rohaan, M. W., Van den Heuvel, N. M. J., Fraterman, I., Delfos, M., van de Poll-Franse, L. V., Borch, T. H., Svane, I. M., Haanen, J. B. A. G., Retèl, V. P., Boekhout, A. H.

“…PURPOSEPatients with advanced melanoma refractory to first-line treatment have a need for effective second-line treatment options. A recent phase 3 trial…”
Get full text

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways by Cleton-Jansen, A-M, Anninga, J K, Briaire-de Bruijn, I H, Romeo, S, Oosting, J, Egeler, R M, Gelderblom, H, Taminiau, A H M, Hogendoorn, P C W

“…Background: Osteosarcoma is the most prevalent primary malignant bone tumour in children and young adults, with poor survival in 40% of patients. To identify…”
Get full text

Choroid plexus tumours by WOLFF, J. E. A, SAJEDI, M, BRANT, R, COPPES, M. J, EGELER, R. M

“…Choroid plexus tumours are rare epithelial brain tumours and limited information is available regarding their biology and the best treatment. A meta-analysis…”
Get full text

IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD by Jol-van der Zijde, C M, Bredius, R G M, Jansen-Hoogendijk, A M, Raaijmakers, S, Egeler, R M, Lankester, A C, van Tol, M J D

“…Anti-thymocyte globulin (ATG), raised in rabbits, is frequently used in allogeneic hematopoietic SCT (HSCT), to prevent graft rejection and acute GVHD. In…”
Get full text

Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience by SLATS, A. M, EGELER, R. M, VAN DER DOES-VAN DEN BERG, A, KORBIJN, C, HÄHLEN, K, KAMPS, W. A, VEERMAN, A. J. P, ZWAAN, C. M

“…We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid…”
Get full text

High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study by Bresters, D, van Gils, I C M, Kollen, W J W, Ball, L M, Oostdijk, W, van der Bom, J G, Egeler, R M

“…The aim of our study was to assess the cumulative incidence and severity (‘burden’) of late effects in a single-centre cohort of childhood haematopoietic stem…”
Get full text

Acute gut GVHD in children: does skin involvement matter? by Gassas, A, Sung, L, Dupuis, A, Schechter, T, Egeler, M, Ali, M

“…Gut GVHD (G-GVHD) is frequently the most severe and difficult to treat compared with skin GVHD. It is unknown if skin involvement with G-GVHD has prognostic…”
Get full text

Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT by Gassas, A, Craig-Barnes, H, Dell, S, Doyle, J, Schechter, T, Sung, L, Egeler, M, Palaniyar, N

“…To prospectively assess whether periodic chest health surveillance is beneficial for the early detection of bronchiolitis obliterans syndrome (BOS) in children…”
Get full text

Late mortality after hematopoietic SCT for a childhood malignancy by Schechter, T, Pole, J D, Darmawikarta, D, Doyle, J, Ali, M, Egeler, M, Gassas, A, Irwin, M S, Greenberg, M, Nathan, P C

“…Hematopoietic SCT (HSCT) has been used as a curative therapy for pediatric malignancies. Survivors of HSCT are at risk for disease recurrence, late morbidity…”
Get full text

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation by Lankester, A C, Bierings, M B, van Wering, E R, Wijkhuijs, A J M, de Weger, R A, Wijnen, J T, Vossen, J M, Versluys, B, Egeler, R M, van Tol, M J D, Putter, H, Révész, T, van Dongen, J J M, van der Velden, V H J, Schilham, M W

“…Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT). A…”
Get full text

Parental stress and perceived vulnerability at 5 and 10 years after pediatric SCT by Vrijmoet-Wiersma, C M J, Egeler, R M, Koopman, H M, Bresters, D, Norberg, A L, Grootenhuis, M A

“…With the aim of assessing parental stress after SCT, 73 parents of children and adolescents who underwent SCT 5 or 10 years ago responded to questionnaires on…”
Get full text

Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation by MIANO, M, LABOPIN, M, PETERS, C, ORTEGA, J, VEYS, P, BORDIGONI, P, IORI, A. P, NIETHAMMER, D, ROCHA, V, DINI, G, HARTMANN, O, ANGELUCCI, E, CORNISH, J, GLUCKMAN, E, LOCATELLI, F, FISCHER, A, EGELER, R. M, OR, R

“…This paper describes the trends in haematopoietic stem cell transplantation (HSCT) activity for children in Europe over the last three decades. We analysed…”
Get full text

A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) by AL-ALI, H. K, BRAND, R, NIEDERWIESER, D, DE WITTE, T, VAN BIEZEN, A, FINKE, J, BOOGAERTS, M, FAUSER, A. A, EGELER, M, CAHN, J.-Y, ARNOLD, R, BIERSACK, H

“…Hematopoietic cell transplantation (HCT) is an effective treatment for myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML). In this study, outcome…”
Get full text

Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity by ZWAVELING, J, BREDIUS, R. G. M, CREMERS, Sclm, BALL, L. M, LANKESTER, A. C, TEEPE-TWISS, I. M, EGELER, R. M, DEN HARTIGH, J, VOSSEN, J. M

“…We studied the pharmacokinetics of intravenous busulfan (Bu) in children in order to further optimize intravenous Bu dosing in relation to toxicity and…”
Get full text

How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more by HEEMSKERK, M. B. A, VAN WALRAVEN, S. M, DONKER, A. E, HOOGERBRUGGE, P. M, VAN ROOD, J. J, CLAAS, F. H. J, OUDSHOORN, M, CORNELISSEN, J. J, BARGE, R. M. Y, BREDIUS, R. G. M, EGELER, R. M, LIE, Jlwtj, REVESZ, T, SINTNICOLAAS, K, WULFFRAAT, N. M

“…Many patients do not reach haematopoietic stem cell transplantation. Shortage of unrelated donors (UDs) is still seen as the main cause. However, with a…”
Get full text

CsA exposure is associated with acute GVHD and relapse in children after SCT by Willemze, A J, Press, R R, Lankester, A C, Egeler, R M, den Hartigh, J, Vossen, J M

“…CsA is commonly used after haematological SCT (HSCT) as GVHD prophylaxis. In solid organ transplantation, area under the blood concentration vs time curve…”
Get full text